Metabolic syndrome components and colorectal adenoma in the CLUE II cohort

Konstantinos K. Tsilidis, Frederick L. Brancati, Michael N. Pollak, Nader Rifai, Sandra L. Clipp, Judith Hoffman-Bolton, Kathy J. Helzlsouer, Elizabeth A Platz

Research output: Contribution to journalArticle

Abstract

Background: Metabolic syndrome components have been associated with colorectal cancer in several studies; however, evidence for colorectal adenomas is limited. Thus, we evaluated the association between markers of the metabolic syndrome with colorectal adenoma development in a nested case-control study. Methods: Colorectal adenoma cases (n = 132) and matched controls, who had a negative sigmoidoscopy or a colonoscopy (n = 260), were identified between baseline in 1989 and 2000 among participants in the CLUE II cohort of Washington County, Maryland. Concentrations of C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured in baseline blood specimens. Body mass index was calculated using baseline height and weight. Use of medications to treat diabetes mellitus was self-reported at baseline. Blood pressure was measured at baseline. Distributional cutpoints of the latter markers were used to define the metabolic syndrome components (hyperinsulinemia, hyperglycemia, obesity, dyslipidemia, and hypertension) present at baseline. Results: No statistically significant associations with adenomas were observed for the markers of the metabolic syndrome, with the exception of a strong positive association for use of diabetes medications (OR, 8.00; 95% CI, 1.70-37.67), albeit based on small numbers. Conclusion: Our findings do not support that components of the metabolic syndrome influence risk of colorectal adenomas, except possibly for severe diabetes mellitus warranting medical treatment.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalCancer Causes and Control
Volume21
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Adenoma
Diabetes Mellitus
Insulin-Like Growth Factor Binding Protein 1
Sigmoidoscopy
C-Peptide
Glycosylated Hemoglobin A
Hyperinsulinism
Colonoscopy
Dyslipidemias
Hyperglycemia
HDL Cholesterol
Case-Control Studies
Colorectal Neoplasms
Body Mass Index
Obesity
Cholesterol
Blood Pressure
Hypertension
Weights and Measures
Therapeutics

Keywords

  • Colorectal neoplasia
  • Insulin resistance
  • Prospective study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tsilidis, K. K., Brancati, F. L., Pollak, M. N., Rifai, N., Clipp, S. L., Hoffman-Bolton, J., ... Platz, E. A. (2010). Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes and Control, 21(1), 1-10. https://doi.org/10.1007/s10552-009-9428-6

Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. / Tsilidis, Konstantinos K.; Brancati, Frederick L.; Pollak, Michael N.; Rifai, Nader; Clipp, Sandra L.; Hoffman-Bolton, Judith; Helzlsouer, Kathy J.; Platz, Elizabeth A.

In: Cancer Causes and Control, Vol. 21, No. 1, 01.2010, p. 1-10.

Research output: Contribution to journalArticle

Tsilidis, KK, Brancati, FL, Pollak, MN, Rifai, N, Clipp, SL, Hoffman-Bolton, J, Helzlsouer, KJ & Platz, EA 2010, 'Metabolic syndrome components and colorectal adenoma in the CLUE II cohort', Cancer Causes and Control, vol. 21, no. 1, pp. 1-10. https://doi.org/10.1007/s10552-009-9428-6
Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes and Control. 2010 Jan;21(1):1-10. https://doi.org/10.1007/s10552-009-9428-6
Tsilidis, Konstantinos K. ; Brancati, Frederick L. ; Pollak, Michael N. ; Rifai, Nader ; Clipp, Sandra L. ; Hoffman-Bolton, Judith ; Helzlsouer, Kathy J. ; Platz, Elizabeth A. / Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. In: Cancer Causes and Control. 2010 ; Vol. 21, No. 1. pp. 1-10.
@article{357844e60a8b4ef79a3369bad00ce2f5,
title = "Metabolic syndrome components and colorectal adenoma in the CLUE II cohort",
abstract = "Background: Metabolic syndrome components have been associated with colorectal cancer in several studies; however, evidence for colorectal adenomas is limited. Thus, we evaluated the association between markers of the metabolic syndrome with colorectal adenoma development in a nested case-control study. Methods: Colorectal adenoma cases (n = 132) and matched controls, who had a negative sigmoidoscopy or a colonoscopy (n = 260), were identified between baseline in 1989 and 2000 among participants in the CLUE II cohort of Washington County, Maryland. Concentrations of C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured in baseline blood specimens. Body mass index was calculated using baseline height and weight. Use of medications to treat diabetes mellitus was self-reported at baseline. Blood pressure was measured at baseline. Distributional cutpoints of the latter markers were used to define the metabolic syndrome components (hyperinsulinemia, hyperglycemia, obesity, dyslipidemia, and hypertension) present at baseline. Results: No statistically significant associations with adenomas were observed for the markers of the metabolic syndrome, with the exception of a strong positive association for use of diabetes medications (OR, 8.00; 95{\%} CI, 1.70-37.67), albeit based on small numbers. Conclusion: Our findings do not support that components of the metabolic syndrome influence risk of colorectal adenomas, except possibly for severe diabetes mellitus warranting medical treatment.",
keywords = "Colorectal neoplasia, Insulin resistance, Prospective study",
author = "Tsilidis, {Konstantinos K.} and Brancati, {Frederick L.} and Pollak, {Michael N.} and Nader Rifai and Clipp, {Sandra L.} and Judith Hoffman-Bolton and Helzlsouer, {Kathy J.} and Platz, {Elizabeth A}",
year = "2010",
month = "1",
doi = "10.1007/s10552-009-9428-6",
language = "English (US)",
volume = "21",
pages = "1--10",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Metabolic syndrome components and colorectal adenoma in the CLUE II cohort

AU - Tsilidis, Konstantinos K.

AU - Brancati, Frederick L.

AU - Pollak, Michael N.

AU - Rifai, Nader

AU - Clipp, Sandra L.

AU - Hoffman-Bolton, Judith

AU - Helzlsouer, Kathy J.

AU - Platz, Elizabeth A

PY - 2010/1

Y1 - 2010/1

N2 - Background: Metabolic syndrome components have been associated with colorectal cancer in several studies; however, evidence for colorectal adenomas is limited. Thus, we evaluated the association between markers of the metabolic syndrome with colorectal adenoma development in a nested case-control study. Methods: Colorectal adenoma cases (n = 132) and matched controls, who had a negative sigmoidoscopy or a colonoscopy (n = 260), were identified between baseline in 1989 and 2000 among participants in the CLUE II cohort of Washington County, Maryland. Concentrations of C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured in baseline blood specimens. Body mass index was calculated using baseline height and weight. Use of medications to treat diabetes mellitus was self-reported at baseline. Blood pressure was measured at baseline. Distributional cutpoints of the latter markers were used to define the metabolic syndrome components (hyperinsulinemia, hyperglycemia, obesity, dyslipidemia, and hypertension) present at baseline. Results: No statistically significant associations with adenomas were observed for the markers of the metabolic syndrome, with the exception of a strong positive association for use of diabetes medications (OR, 8.00; 95% CI, 1.70-37.67), albeit based on small numbers. Conclusion: Our findings do not support that components of the metabolic syndrome influence risk of colorectal adenomas, except possibly for severe diabetes mellitus warranting medical treatment.

AB - Background: Metabolic syndrome components have been associated with colorectal cancer in several studies; however, evidence for colorectal adenomas is limited. Thus, we evaluated the association between markers of the metabolic syndrome with colorectal adenoma development in a nested case-control study. Methods: Colorectal adenoma cases (n = 132) and matched controls, who had a negative sigmoidoscopy or a colonoscopy (n = 260), were identified between baseline in 1989 and 2000 among participants in the CLUE II cohort of Washington County, Maryland. Concentrations of C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured in baseline blood specimens. Body mass index was calculated using baseline height and weight. Use of medications to treat diabetes mellitus was self-reported at baseline. Blood pressure was measured at baseline. Distributional cutpoints of the latter markers were used to define the metabolic syndrome components (hyperinsulinemia, hyperglycemia, obesity, dyslipidemia, and hypertension) present at baseline. Results: No statistically significant associations with adenomas were observed for the markers of the metabolic syndrome, with the exception of a strong positive association for use of diabetes medications (OR, 8.00; 95% CI, 1.70-37.67), albeit based on small numbers. Conclusion: Our findings do not support that components of the metabolic syndrome influence risk of colorectal adenomas, except possibly for severe diabetes mellitus warranting medical treatment.

KW - Colorectal neoplasia

KW - Insulin resistance

KW - Prospective study

UR - http://www.scopus.com/inward/record.url?scp=74149084208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149084208&partnerID=8YFLogxK

U2 - 10.1007/s10552-009-9428-6

DO - 10.1007/s10552-009-9428-6

M3 - Article

C2 - 19774471

AN - SCOPUS:74149084208

VL - 21

SP - 1

EP - 10

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 1

ER -